Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.
Valgimigli, Marco; Frigoli, Enrico; Leonardi, Sergio; Rothenbühler, Martina; Gagnor, Andrea; Calabrò, Paolo; Garducci, Stefano; Rubartelli, Paolo; Briguori, Carlo; Andò, Giuseppe; Repetto, Alessandra; Limbruno, Ugo; Garbo, Roberto; Sganzerla, Paolo; Russo, Filippo; Lupi, Alessandro; Cortese, Bernardo; Ausiello, Arturo; Ierna, Salvatore; Esposito, Giovanni; Presbitero, Patrizia; Santarelli, Andrea; Sardella, Gennaro; Varbella, Ferdinando; Tresoldi, Simone; de Cesare, Nicoletta; Rigattieri, Stefano; Zingarelli, Antonio; Tosi, Paolo; van 't Hof, Arnoud; Boccuzzi, Giacomo; Omerovic, Elmir; Sabaté, Manel; Heg, Dik; Jüni, Peter; Vranckx, Pascal.
N Engl J Med
; 373(11): 997-1009, 2015 Sep 10.
Artigo em Inglês | MEDLINE | ID: mdl-26324049
Heparin versus placebo for non-ST elevation acute coronary syndromes.
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
Heparin versus placebo for acute coronary syndromes.
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
How one academic medical center has managed potency changes with unfractionated heparin.
Bivalirudin during primary PCI in acute myocardial infarction.
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions.
Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.